[1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:

wherein:

m is 1;

V is selected from

X is selected from a bond, O and N(R a ); where R a is selected from hydrogen and C 1-6 alkyl;

each occurrence of R 1 and R 2 is independently selected from:

(i) hydrogen,

(ii) C 1-6 alkyl, and

(iii) C 3-6 cycloalkyl;

or alternatively, le and R 2 together with the carbon to which they are attached form a C 3-6 cycloalkyl or a 4-6 membered heterocyclyl; wherein the C 3-6 cycloalkyl is optionally substituted with C 1-6 alkyl; and

each occurrence of R 3 and R 4 is independently selected from:

(i) C 1-6 alkyl, optionally substituted with one to four substituents independently selected from halogen and phenyl,

(ii) C 3-6 cycloalkyl,

(iii) aryl, and

(iv) heterocyclyl;

wherein each of the phenyl of (i), aryl of (iii) and heterocyclyl of (iv) is optionally substituted with one to four substituents independently selected from:

(a) halogen,

(b) C 1-6 alkyl, optionally substituted with one to four halogens,

(c) —O—C 1-6 alkyl, optionally substituted with one to four halogens,

(d) C 3-6 cycloalkyl, optionally substituted with one to four halogens, and

(e) —CN.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

each occurrence of R 1 and R 2 is independently selected from:

(i) hydrogen,

(ii) C 1-6 alkyl, and

(iii) C 3-6 cycloalkyl;

or alternatively, R 1 and R 2 together with the carbon to which they are attached form a C 3-6 cycloalkyl or a 4-6 membered saturated heterocyclyl; wherein the C 3-6 cycloalkyl is optionally substituted with C 1-6 alkyl.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 1 is hydrogen; and

R 2 is methyl;

or alternatively, R 1 and R 2 together with the carbon to which they are attached form a C 3-6 cycloalkyl or oxetanyl; wherein the C 3-6 cycloalkyl is optionally substituted with methyl.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from:

(i) phenyl,

(ii) naphthyl and

(iii) pyridinyl;

wherein each of the phenyl of (i), naphthyl of (ii) and pyridinyl of (iii) is optionally substituted with one to four substituents independently selected from:

(a) halogen, and

(b) C 1-6 alkyl, optionally substituted with one to three halogens.

5. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from:

(i) phenyl, and

(ii) pyridinyl;

wherein each of the phenyl of (i) and pyridinyl of (ii) is optionally substituted with a halogen.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from:

(i) phenyl,

(ii) naphthyl and

(iii) a heterocyclyl selected from furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrahydropyrazinyl, tetrahydropyridazinyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, thiophenyl, triazolyl, imidazo[1,5-a]pyridinyl, indolinyl, indolizinyl, isoquinolinyl, pyrazolo[1,5-a]pyridinyl, quinolinyl, 4,5,6,7-tetrahydro-1,2-benzoxazolyl and triazolo[1,5-a]pyridinyl;

wherein each of the phenyl of (i), naphthyl of (ii) and heterocyclyl of (iii) is optionally substituted with one to four substituents independently selected from:

(a) halogen,

(b) C 1-6 alkyl, optionally substituted with one to four halogens,

(c) —O—C 1-6 alkyl, optionally substituted with one to four halogens,

(d) C 3-6 cycloalkyl, optionally substituted with one to four halogens, and

(e) —CN.

7. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from:

(i) phenyl, and

(ii) a heterocyclyl selected from isoxazolyl, oxadiazolyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, thiazolyl, imidazo[1,5-a]pyridinyl, indolinyl, indolizinyl, isoquinolinyl, pyrazolo[1,5-a]pyridinyl, quinolinyl, 4,5,6,7-tetrahydro-1,2-benzoxazolyl and triazolo[1,5-a]pyridinyl;

wherein each of the phenyl of (i) and heterocyclyl of (ii) is optionally substituted with one to three substituents independently selected from:

(a) halogen,

(b) C 1-4 alkyl, optionally substituted with one to four halogens,

(c) —O—C 1-4 alkyl, optionally substituted with one to four halogens, and

(d) CN.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

each occurrence of R 1 and R 2 is independently selected from:

(i) hydrogen,

(ii) C 1-6 alkyl, and

(iii) C 3-6 cycloalkyl;

or alternatively, R 1 and R 2 together with the carbon to which they are attached form a C 3-6 cycloalkyl;

R 3 is selected from:

(i) phenyl,

(ii) naphthyl and

(iii) pyridinyl;

wherein each of the phenyl of (i), naphthyl of (ii) and pyridinyl of (iii) is optionally substituted with one to four substituents independently selected from:

(a) halogen, and

(b) C 1-6 alkyl; and

R 4 is selected from:

(i) phenyl,

(ii) naphthyl and

(iii) a heterocyclyl selected from isoxazolyl, oxadiazolyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, thiazolyl, imidazo[1,5-a]pyridinyl, indolinyl, indolizinyl, isoquinolinyl, pyrazolo[1,5-a]pyridinyl, quinolinyl, 4,5,6,7-tetrahydro-1,2-benzoxazolyl and triazolo[1,5-a]pyridinyl;

wherein each of the phenyl of (i), naphthyl of (ii) and heterocyclyl of (iii) is optionally substituted with one to four substituents independently selected from:

(a) halogen,

(b) C 1-6 alkyl, optionally substituted with one to four halogens,

(c) —O—C 1-6 alkyl, optionally substituted with one to four halogens, and

(d) CN.

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 1 is hydrogen;

R 2 is selected from:

(i) hydrogen, and

(ii) C 1-6 alkyl;

or alternatively, le and R 2 together with the carbon to which they are attached form a C 3-6 cycloalkyl;

R 3 is selected from:

(i) phenyl, and

(ii) pyridinyl;

wherein each of the phenyl of (i) and pyridinyl of (ii) is optionally substituted with a halogen; and

R 4 is selected from:

(i) phenyl,

(ii) naphthyl and

(iii) a heterocyclyl selected from isoxazolyl, oxadiazolyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, thiazolyl, imidazo[1,5-a]pyridinyl, indolinyl, indolizinyl, isoquinolinyl, pyrazolo[1,5-a]pyridinyl, quinolinyl, 4,5,6,7-tetrahydro-1,2-benzoxazolyl and triazolo[1,5-a]pyridinyl;

wherein each of the phenyl of (i), naphthyl of (ii) and heterocyclyl of (iii) is optionally substituted with one to four substituents independently selected from:

(a) halogen,

(b) C 1-4 alkyl, optionally substituted with one to four halogens,

(c) —O—C 1-4 alkyl, optionally substituted with one to four halogens, and

(d) CN.

10. The compound of claim 1 of formula (Ib), or a pharmaceutically acceptable salt thereof:

wherein:

R 1 is hydrogen;

R 2 is selected from:

(i) hydrogen, and

(ii) C 1-6 alkyl;

or alternatively, le and R 2 together with the carbon to which they are attached form a C 3-6 cycloalkyl or a 4-6 membered saturated heterocyclyl;

R 3 is selected from:

(i) phenyl, and

(ii) pyridinyl;

wherein each of the phenyl of (i) and pyridinyl of (ii) is optionally substituted with a halogen; and

R 4 is selected from:

(i) phenyl,

(ii) naphthyl and

(iii) a heterocyclyl selected from isoxazolyl, oxadiazolyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, thiazolyl, imidazo[1,5-a]pyridinyl, indolinyl, indolizinyl, isoquinolinyl, pyrazolo[1,5-a]pyridinyl, quinolinyl, 4,5,6,7-tetrahydro-1,2-benzoxazolyl and triazolo[1,5-a]pyridinyl;

wherein each of the phenyl of (i), naphthyl of (ii) and heterocyclyl of (iii) is optionally substituted with one to four substituents independently selected from:

(a) halogen,

(b) C 1-4 alkyl, optionally substituted with one to four halogens,

(c) —O—C 1-4 alkyl, optionally substituted with one to four halogens, and

(d) CN.

11. The compound of claim 1 of formula (Id), or a pharmaceutically acceptable salt thereof:

wherein:

n is 1, 2 or 3;

V is selected from

X is selected from a bond, O and N(R a ); wherein R a is selected from hydrogen and methyl;

R 3 is selected from:

(i) phenyl, and

(ii) pyridinyl;

wherein each of the phenyl of (i) and pyridinyl of (ii) is optionally substituted with a halogen; and

R 4 is selected from:

(i) phenyl,

(ii) naphthyl and

(iii) a heterocyclyl selected from isoxazolyl, oxadiazolyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, thiazolyl, imidazo[1,5-a]pyridinyl, indolinyl, indolizinyl, isoquinolinyl, pyrazolo[1,5-a]pyridinyl, quinolinyl, 4,5,6,7-tetrahydro-1,2-benzoxazolyl and triazolo[1,5-a]pyridinyl;

wherein each of the phenyl of (i), naphthyl of (ii) and heterocyclyl of (iii) is optionally substituted with one to four substituents independently selected from:

(a) halogen,

(b) C 1-4 alkyl, optionally substituted with one to four halogens,

(c) —O—C 1-4 alkyl, optionally substituted with one to four halogens, and

(d) CN.

12. The compound of claim 1 of formula (If), or a pharmaceutically acceptable salt thereof:

wherein:

R 1 is hydrogen;

R 2 is selected from:

(i) hydrogen, and

(ii) C 1-6 alkyl;

or alternatively, le and R 2 together with the carbon to which they are attached form a C 3-6 cycloalkyl;

R 3 is selected from:

(i) phenyl, and

(ii) pyridinyl;

wherein each of the phenyl of (i) and pyridinyl of (ii) is optionally substituted with a halogen; and

R 4 is selected from:

(i) C 1-6 alkyl, optionally substituted with an aryl; and

(ii) C 3-6 cycloalkyl.

13. The compound of claim 1 of formula (Ih), or a pharmaceutically acceptable salt thereof:

wherein:

V is selected from

X is selected from a bond, O and N(R a ); wherein R a is selected from hydrogen and methyl;

R 3 is selected from:

(i) phenyl, and

(ii) pyridinyl;

wherein each of the phenyl of (i) and pyridinyl of (ii) is optionally substituted with a halogen; and

R 4 is selected from:

(i) phenyl,

(ii) naphthyl and

(iii) a heterocyclyl selected from isoxazolyl, oxadiazolyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, thiazolyl, imidazo[1,5-a]pyridinyl, indolinyl, indolizinyl, isoquinolinyl, pyrazolo[1,5-a]pyridinyl, quinolinyl, 4,5,6,7-tetrahydro-1,2-benzoxazolyl and triazolo[1,5-a]pyridinyl;

wherein each of the phenyl of (i), naphthyl of (ii) and heterocyclyl of (iii) is optionally substituted with one to four substituents independently selected from:

(a) halogen,

(b) C 1-4 alkyl, optionally substituted with one to four halogens,

(c) —O—C 1-4 alkyl, optionally substituted with one to four halogens, and

(d) CN.

14. A compound selected from:

3-chloro-N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

3-chloro-N-(3-(1-((4-fluorophenyl) carbamoyl) cyclobutyl) bicyclo [1.1.1] pentan-1-yl) benzamide,

3-cyano-N-(3-(1-((4-fluorophenyl)carbamoyl)cyclobutyl)bicyclo[1.1.1]pentan-1-yl)benzamide,

3,4-dichloro-N-(3-(1-((4-fluorophenyl)carbamoyl)cyclobutyl)bicyclo[1.1.1]pentan-1-yl)benzamide,

3-chloro-N-(3-(1-((4-chlorophenyl)amino)-1-oxopropan-2-yl)bicyclo [1.1.1] pentan-1-yl) benzamide,

3,4-dichloro-N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

3-chloro-N-(3-(1-((4-chloro-3-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

N-(3-(1-((4-chlorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)-3-cyanobenzamide,

3,4-dichloro-N-(3-(1-((6-fluoropyridin-3-yl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

3-chloro-N-(3-(1-((6-chloropyridin-3-yl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

N-(3-(1-((6-chloropyridin-3-yl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)bicyclo[4.2.0]octa-1(6),2,4-triene-3-carboxamide,

cyclopropyl (3-(1-((4-chlorophenyl)amino)-1-oxopropan-2-yl)bicyclo [1.1.1] pentan-1-yl) carbamate,

3, 4-dichloro-N-(3-(1-(4-fluorobenzamido)ethyl) bicyclo [1.1.1] pentan-1-yl) benzamide, benzyl (3-(1-(4-fluorobenzamido)cyclopropyl)bicyclo[1.1.1]pentan-1-yl)carbamate,

3,4-dichloro-N-(3-(1-(4-fluorobenzamido)cyclopropyl)bicyclo[1.1.1]pentan-1-yl)benzamide,

5-chloro-N-(3-(1-(4-fluorobenzamido)cyclopropyl)bicyclo[1.1.1]pentan-1-yl)pi colinamide,

N-(3-(1-(4-fluorobenzamido)cyclopropyl)bicyclo[1.1.1]pentan-1-yl)-5-(trifluoromethyl)picolinamide,

4-(difluoromethyl)-N-(3-(1-(4-fluorobenzamido)cyclopropyl)bicyclo[1.1.1]pen tan-1-yl)picolinamide,

N-(3-(1-(4-fluorobenzamido)cyclopropyl)bicyclo[1.1.1]pentan-1-yl)-3-methyl-1,2,4-oxadiazole-5-carboxamide,

3-cyclopropyl-N-(3-(1-(4-fluorobenzamido)cyclopropyl)bicyclo[1.1.1]pentan-1-yl)-1,2,4-oxadiazole-5-carboxamide,

N-(3-(1-(4-fluorobenzamido)cyclopropyl)bicyclo[1.1.1]pentan-1-yl)-5-methyl-1,2,4-oxadiazole-3-carboxamide,

tert-butyl (R)-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)carbamate,

tert-butyl (S)-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)carbamate,

(R)-6-chloro-N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)picolinamide,

(S)-6-chloro-N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)picolinamide,

3-chloro-4-fluoro-N-[3-[(1R)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]benzamide,

3-chloro-N-[3-[(1R)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-4-methyl-benzamide,

4-chloro-N-[3-[(1R)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-3-methyl-benzamide,

3-chloro-2-fluoro-N-[3-[(1R)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]benzamide,

4-fluoro-N-[3-[(1R)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-3-methyl-benzamide,

3-chloro-5-fluoro-N-[3-[(1R)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]benzamide,

3-fluoro-N-[3-[(1R)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-4-methyl-benzamide,

N-[3-[(1R)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-3-(trifluoromethyl)benzamide,

3,4-difluoro-N-[3-[(1R)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]benzamide,

3-chloro-N-[3-[(1R)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-4-methyl-benzamide,

4-chloro-N-[3-[(1R)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-3-methyl-benzamide,

4-fluoro-N-[3-[(1R)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-3-methyl-benzamide,

4-chloro-3-fluoro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]benzamide,

3-chloro-4-fluoro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]benzamide,

3-chloro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-4-methyl-benzamide,

4-chloro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-3-methyl-benzamide,

3-chloro-2-fluoro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]benzamide,

4-chloro-2-fluoro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]benzamide,

3-chloro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-2-methyl-benzamide,

4-fluoro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-3-methyl-benzamide,

3-chloro-5-fluoro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]benzamide,

5-chloro-2-fluoro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]benzamide,

N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-4-methyl-pyrimidin-1-ium-2-carboxamide,

3-fluoro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-4-methyl-benzamide,

5-chloro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]pyridin-1-ium-3-carboxamide,

6-chloro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]pyridin-1-ium-3-carboxamide,

6-chloro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-5-methyl-pyridin-1-ium-2-carboxamide,

N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-3-(trifluoromethyl)benzamide,

5,6-dichloro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]pyridin-1-ium-3-carboxamide,

N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-5,6-dimethyl-pyridin-1-ium-2-carboxamide,

5-fluoro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-6-methyl-pyridin-1-ium-3-carboxamide,

N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-2-(trifluoromethyl)pyridin-1-ium-4-carboxamide,

4-fluoro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-3-methoxy-benzamide,

N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-5-(trifluoromethyl)pyridin-1-ium-3-carboxamide,

3,4-difluoro-N-[3-[(1S)-2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]benzamide,

(S)—N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)-2-naphthamide,

(S)-5,6-dichloro-N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)picolinamide,

(S)—N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)-6-(trifluoromethyl)picolinamide,

(S)-3-chloro-4-cyano-N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

(S)-4-cyano-N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)-3-methylbenzamide,

(S)—N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)quinoline-7-carboxamide,

(S)—N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)-6-(trifluoromethyl)nicotinamide,

cyclopentyl (S)-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)carbamate,

benzyl (S)-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)carbamate,

isopropyl (S)-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)carbamate,

cyclopropyl (S)-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)carbamate,

(S)-2-(3-(3-(3-chlorophenyl)ureido)bicyclo[1.1.1]pentan-1-yl)-N-(4-fluorophenyl)propanamide,

(S)-2-(3-(3-(3,4-difluorophenyl)ureido)bicyclo[1.1.1]pentan-1-yl)-N-(4-fluorophenyl)propanamide,

(S)-2-(3-(3-(3-chloro-4-fluorophenyl)ureido)bicyclo[1.1.1]pentan-1-yl)-N-(4-fluorophenyl)propanamide,

(S)-2-(3-(3-(3-chloro-2-methylphenyl)ureido)bicyclo[1.1.1]pentan-1-yl)-N-(4-fluorophenyl)propanamide,

(S)—N-(4-fluorophenyl)-2-(3-(3-(4-fluorophenyl)ureido)bicyclo[1.1.1]pentan-1-yl)propanamide,

(S)—N-(4-fluorophenyl)-2-(3-(3-(naphthalen-1-yl)ureido)bicyclo[1.1.1]pentan-1-yl)propanamide,

(S)—N-(4-fluorophenyl)-2-(3-(3-(3-(trifluoromethyl)phenyl)ureido)bicyclo[1.1.1]pentan-1-yl)propanamide,

(R)-3,4-dichloro-N-(3-(1-((5,6-difluoropyridin-3-yl)amino)-1-oxopropan-2-yl) bicyclo[1.1.1]pentan-1-yl)benzamide,

(R)-3,4-dichloro-N-(3-(1-((6-chloro-5-fluoropyridin-3-yl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

(R)-3,4-dichloro-N-(3-(1-((2-chloropyrimidin-5-yl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

(R)-3,4-dichloro-N-(3-(1-((3,4-difluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

(R)-3,4-dichloro-N-(3-(1-oxo-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

(S)-3,4-dichloro-N-(3-(1-((5,6-dichloropyridin-3-yl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

(S)-3-chloro-5-(2-(3-(3,4-dichlorobenzamido)bicyclo[1.1.1]pentan-1-yl)propanamido)pyridin-1-ium,

(S)-3,4-dichloro-N-(3-(1-((4-fluoro-3-(trifluoromethyl)phenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

(S)-3,4-dichloro-N-(3-(1-((3-chloro-4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

(S)-3,4-dichloro-N-(3-(1-((3,4-difluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

(S)-3,4-dichloro-N-(3-(1-oxo-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

(S)-3,4-dichloro-N-(3-(1-oxo-1-((3-(trifluoromethyl)phenyl)amino)propan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

3,4-dichloro-N-(3-(1-((4-fluorophenyl)carbamoyl)cyclopropyl)bicyclo[1.1.1]pentan-1-yl)benzamide,

3,4-dichloro-N-(3-(1-((4-fluorophenyl)amino)-2-methyl-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

3-chloro-N-(3-(1-((4-fluorophenyl)amino)-2-methyl-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

3,4-dichloro-N-(3-(2-(4-fluorobenzamido)propan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

3-(3-(3-chlorobenzamido)bicyclo[1.1.1]pentan-1-yl)-N-(4-fluorophenyl)oxetane-3-carboxamide,

3-(3-(3-chlorobenzamido)bicyclo[1.1.1]pentan-1-yl)-N-(3,4-difluorophenyl)oxetane-3-carboxamide,

3-(3-(3,4-difluorobenzamido)bicyclo[1.1.1]pentan-1-yl)-N-(4-fluorophenyl)oxetane-3-carboxamide,

3-(3-(3,4-difluorobenzamido)bicyclo[1.1.1]pentan-1-yl)-N-(3,4-difluorophenyl)oxetane-3-carboxamide,

N-(4-chlorophenyl)-3-(3-(3,4-difluorobenzamido)bicyclo[1.1.1]pentan-1-yl)oxetane-3-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-3-(trifluoromethoxy)benzamide,

5-ethyl-N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]isoxazole-3-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]imidazo[1,5-a]pyridin-2-ium-5-carboxamide,

4-chloro-N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]pyridin-1-ium-2-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]pyrazolo[1,5-a]pyridin-1-ium-3-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-3-methyl-1,2,4-oxadiazole-5-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-4,5,6,7-tetrahydro-1,2-benzoxazole-3-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]indolizine-2-carboxamide,

4-ethyl-N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]pyridin-1-ium-2-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-4-methyl-pyridin-1-ium-2-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-6-methyl-pyridin-1-ium-2-carboxamide,

5-cyclopropyl-N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]isoxazole-3-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-2-oxo-indoline-4-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-5-methyl-pyridin-1-ium-3-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-2-methyl-thiazole-4-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-5-methyl-pyrazolo[1,5-a]pyridin-1-ium-3-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-2-methoxy-pyridin-1-ium-4-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]pyrazolo[1,5-a]pyridin-1-ium-7-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]indolizine-1-carboxamide,

N-(4-fluorophenyl)-2-[3-[[2-[2-(trifluoromethyl)phenyl]acetyl]amino]-1-bicyclo[1.1.1]pentanyl]propanamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]pyridin-1-ium-2-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]isoquinolin-2-ium-8-carboxamide,

1-(difluoromethyl)-N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]pyrazole-3-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-6-methyl-pyridin-1-ium-3-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-5-(trifluoromethyl)pyridin-1-ium-2-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]isoquinolin-2-ium-5-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]cinnoline-4-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-2,4-dimethyl-thiazole-5-carboxamide,

3-fluoro-N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]pyridin-1-ium-2-carboxamide,

6-ethoxy-N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]pyridin-1-ium-2-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-2,5-dimethyl-pyrazole-3-carboxamide,

5-chloro-N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]pyrazine-2-carboxamide,

5-ethyl-N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]-2-methyl-pyrazole-3-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]pyridin-1-ium-3-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]triazolo[1,5-a]pyridin-1-ium-4-carboxamide,

N-[3-[2-(4-fluoroanilino)-1-methyl-2-oxo-ethyl]-1-bicyclo[1.1.1]pentanyl]isoquinolin-2-ium-3-carboxamide,

(S)-3,4,5-trifluoro-N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

(S)—N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)-6-(trifluoromethyl)nicotinamide,

(S)—N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)quinoline-7-carboxamide,

(S)—N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)-2-naphthamide,

(S)-5,6-dichloro-N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)picolinamide,

(S)-3-chloro-4-cyano-N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide,

(S)-4-cyano-N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)-3-methylbenzamide,

(S)—N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)-6-(trifluoromethyl)picolinamide,

(S)-3,5-difluoro-N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide, and

(S)-2,4,5-trifluoro-N-(3-(1-((4-fluorophenyl)amino)-1-oxopropan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzamide;

or a pharmaceutically acceptable salt thereof.

15. A composition which comprises an inert carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.

16. A method for treating or preventing an IDO-associated disease or disorder in a mammalian subject which comprises administering to the subject an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

17. A method for treating an IDO-associated disease or disorder in a mammalian subject which comprises administering to the subject an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof in combination with another anti-cancer agent.

18. The method of claim 16 , wherein the IDO-associated disease or disorder is a cancer, viral infection, HCV infection, depression, neurodegenerative disorders, trauma, age-related cataracts, organ transplantation, and autoimmune diseases.

19. The method of claim 18 , wherein the cancer is selected from colon cancer, pancreas cancer, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testes cancer, renal cancer, head and neck cancer, lymphoma, leukemia and melanoma.